RECK in osteosarcoma: A novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model

Cancer

Volumn 117, Issue 15, 2011, Pages 3517-3528

  Clark, Jonathan C M ^a   Akiyama, Toru ^a   Thomas, David M ^b   Labrinidis, Agatha ^c   Evdokiou, Andreas ^c   Galloway, Stuart J ^d   Kim, Han Soo ^e   Dass, Crispin R ^a   Choong, Peter F M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e Seoul National University Hospital   (South Korea)

Author keywords

angiogenesis; matrix metalloproteinases; osteosarcoma; RECK; VEGF

Indexed keywords

COLLAGEN TYPE 1; GELATINASE B; MEMBRANE PROTEIN; PRO MATRIX METALLOPROTEINASE 9; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIFS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; COCULTURE TECHNIQUES; DNA PRIMERS; GPI-LINKED PROTEINS; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79960699931     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25757     Document Type: Article

References (32)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-790. (Pubitemid 34111386)
2. Robertson JH, Hollinger MJ, Wilson C,. Toxicity of doxorubicin and methotrexate in osteogenic sarcoma. BMJ. 1976; 1: 23.
3. Clark JC, Thomas DM, Choong PF, Dass CR,. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 2007; 26: 675-683. (Pubitemid 350115122)
4. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001; 107: 789-800. (Pubitemid 34033671)
5. Kang HG, Kim HS, Kim KJ, et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007; 25: 696-702.
6. Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009; 119: 837-851.
7. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005; 65: 1748-1754. (Pubitemid 40478600)
8. Akiyama T, Choong PF, Dass CR,. RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis. 2010; 27: 207-215.
9. Dass CR, Ek ET, Contreras KG, Choong PF,. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis. 2006; 23: 367-380. (Pubitemid 46197119)
10. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 2005; 22: 319-329. (Pubitemid 41374288)
11. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL Jr,. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res. 1993; 53: 4890-4895. (Pubitemid 23326183)
12. Ayala G, Liu C, Nicosia R, Horowitz S, Lackman R,. Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol. 2000; 31: 341-346. (Pubitemid 30161353)
13. Scotlandi K, Serra M, Manara MC, et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer. 1995; 75: 806-814.
14. Takeuchi T, Hisanaga M, Nagao M, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res. 2004; 10: 5572-5579. (Pubitemid 39100498)
15. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006; 444: 1032-1037. (Pubitemid 46018516)
16. Takagi S, Simizu S, Osada H,. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res. 2009; 69: 1502-158.
17. Chang HC, Liu LT, Hung WC,. Involvement of histone deacetylation in ras-induced down-regulation of the metastasis suppressor RECK. Cell Signal. 2004; 16: 675-679.
18. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A. 1998; 95: 13221-13226. (Pubitemid 28509552)
19. Lodwick GS, Wilson AJ, Farrell C, Virtama P, Dittrich F,. Determining growth rates of focal lesions of bone from radiographs. Radiology. 1980; 134: 577-583. (Pubitemid 10157118)
20. Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008; 456: 814-818.
21. Lobov IB, Renard RA, Papadopoulos N, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A. 2007; 104: 3219-3224. (Pubitemid 46364140)
22. Masui T, Doi R, Koshiba T, et al. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res. 2003; 9: 1779-1784. (Pubitemid 36554604)
23. Chang CK, Hung WC, Chang HC,. The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med. 2008; 12: 2781-2789.
24. Maupas-Schwalm F, Bedel A, Auge N, et al. Integrin alpha (v) beta, metalloproteinases, and sphingomyelinase-2 mediate urokinase mitogenic effect. Cell Signal. 2009; 21: 1925-1934.
25. Tanaka S, Nakamura K, Takahasi N, Suda T,. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev. 2005; 208: 30-49. (Pubitemid 41746383)
26. Stoch SA, Wagner JA,. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther. 2008; 83: 172-176.
27. Dong Z, Bonfil RD, Chinni S, et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol. 2005; 166: 1173-1186. (Pubitemid 40524441)
28. Irie K, Tsuruga E, Sakakura Y, Muto T, Yajima T,. Immunohistochemical localization of membrane type 1-matrix metalloproteinase (MT1-MMP) in osteoclasts in vivo. Tissue Cell. 2001; 33: 478-482. (Pubitemid 33080964)
29. Malik FA, Sanders AJ, Kayani MA, Jiang WG,. Effect of expressional alteration of KAI1 on breast cancer cell growth, adhesion, migration and invasion. Cancer Genomics Proteomics. 2009; 6: 205-213.
30. Morioka Y, Monypenny J, Matsuzaki T, et al. The membrane-anchored metalloproteinase regulator RECK stabilizes focal adhesions and anterior-posterior polarity in fibroblasts. Oncogene. 2009; 28: 1454-1464.
31. Silveira Correa TC, Massaro RR, Brohem CA, et al. RECK-mediated inhibition of glioma migration and invasion. J Cell Biochem. 2010; 110: 52-61.
32. Dohn MR, Brown MV, Reynolds AB,. An essential role for p120-catenin in Src- and Rac1-mediated anchorage-independent cell growth. J Cell Biol. 2009; 184: 437-450.